Overview

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Status:
Active, not recruiting

Trial end date:
2033-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

The First People's Hospital of Changzhou

Treatments:

Apatinib